Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $20.89

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned a consensus recommendation of “Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $20.89.

A number of equities analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Oppenheimer started coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th.

Y-mAbs Therapeutics Stock Down 3.4 %

NASDAQ YMAB opened at $8.28 on Monday. The company has a 50-day moving average price of $12.36 and a 200-day moving average price of $12.57. Y-mAbs Therapeutics has a 52 week low of $6.10 and a 52 week high of $20.90. The firm has a market capitalization of $370.85 million, a P/E ratio of -15.33 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the prior year, the company posted ($0.18) earnings per share. As a group, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of YMAB. Principal Financial Group Inc. purchased a new stake in Y-mAbs Therapeutics in the 3rd quarter worth $267,000. Barclays PLC boosted its stake in Y-mAbs Therapeutics by 433.4% during the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after buying an additional 56,244 shares during the last quarter. Empire Financial Management Company LLC purchased a new position in Y-mAbs Therapeutics during the 3rd quarter valued at approximately $210,000. Geode Capital Management LLC increased its stake in Y-mAbs Therapeutics by 6.2% in the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares during the last quarter. Finally, State Street Corp increased its stake in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.